Petri
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Petri.
Key people at Petri.
# High-Level Overview
Petri is a venture capital firm focused on funding formation-stage startups at the intersection of biology and technology, with applications to planetary and human health[3][5]. The firm operates with a mission to support founders pushing the frontier of biotechnology to tackle significant challenges in healthcare and environmental sustainability. Petri's investment philosophy centers on early-stage companies—from idea and patent stage through prototype, early revenue, and scaling phases—with check sizes ranging from $100,000 to $6 million[3].
The firm is headquartered in Boston, Massachusetts, positioning itself within a robust biotech and life sciences ecosystem[3]. By focusing on the convergence of biology and engineering, Petri addresses a critical gap in venture funding for deep science startups that require specialized capital and expertise during their most formative stages.
Petri emerged as a response to the growing need for dedicated capital in the biotech and synthetic biology space. The firm's founding reflects a broader recognition that formation-stage companies at the biology-technology intersection require investors who understand both the scientific complexity and the commercial potential of these ventures[3][5]. While specific founding details about key partners and the exact year of establishment are limited in available information, the firm's Boston headquarters places it within proximity to major academic institutions and biotech clusters that have historically driven innovation in life sciences.
The firm made its first notable investment in Compound Foods as part of a Seed VC round on August 31, 2021, demonstrating early commitment to supporting companies building at this critical intersection[1].
Petri's primary differentiator is its exclusive focus on startups operating at the intersection of biology and engineering. This narrow thesis allows the firm to develop deep expertise in evaluating scientific feasibility, regulatory pathways, and commercial viability in ways that generalist venture firms cannot[3][5].
Unlike many venture firms that focus on later-stage rounds, Petri specializes in pre-seed and seed funding, supporting companies when they are most vulnerable and when capital is scarce. This positions the firm as a crucial early validator for founders with breakthrough scientific ideas[3][5].
The firm's $100,000 to $6 million check size range is calibrated for formation-stage companies, allowing for meaningful capital deployment without requiring the massive rounds that later-stage investors demand[3].
Petri targets startups across multiple countries—including the USA, UK, Japan, Israel, Canada, Mexico, Brazil, France, Germany, and China—while maintaining focus on specific sectors where biology and technology intersect[3].
Petri operates within a transformative moment for biotech venture capital. The convergence of synthetic biology, computational biology, AI-driven drug discovery, and biotechnology has created unprecedented opportunities for startups to solve problems previously thought intractable. The firm rides several powerful trends: the democratization of biotech tools, the rise of AI applications in life sciences, and growing capital allocation toward climate and health solutions.
The timing is particularly significant as traditional pharmaceutical and biotech companies increasingly struggle with innovation velocity, creating space for nimble startups to capture market share. Petri's early-stage focus means the firm can identify and support founders before larger institutional investors recognize the opportunity, potentially capturing significant upside while building a portfolio of transformative companies.
By concentrating on formation-stage funding, Petri also influences the broader ecosystem by validating scientific approaches and de-risking early-stage teams, making it easier for downstream investors to commit capital with greater confidence.
Petri is positioned at the frontier of a venture capital megatrend: the professionalization and scaling of deep science funding. As regulatory frameworks around synthetic biology mature, as computational tools become more accessible, and as climate and health challenges demand novel solutions, the firm's thesis becomes increasingly relevant.
The future likely holds expanded portfolio growth, potential follow-on fund raises, and increasing visibility as portfolio companies achieve meaningful milestones. The firm's success will ultimately be measured not just by capital returns, but by the transformative impact of the companies it funds—whether in developing novel therapeutics, sustainable materials, or climate solutions. In an era where venture capital is increasingly scrutinized for its societal impact, Petri's explicit focus on planetary and human health positions it as a firm that can deliver both financial returns and meaningful progress on humanity's most pressing challenges.
Key people at Petri.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 1, 2022 | Tessera Therapeutics | $300.0M Series C | — | Catalio Capital, Flagship Ventures |
| Oct 1, 2018 | Axcella | $59.0M Series E | — | Catalio Capital, Flagship Ventures, Daniel Lynch, Third Rock Ventures |
| May 1, 2015 | Axcella | $39.0M Series C | — | Catalio Capital, Flagship Ventures, Daniel Lynch, Third Rock Ventures |
| Oct 1, 2013 | Axcella | $11.0M Series A | — | Catalio Capital, Flagship Ventures, Daniel Lynch, Third Rock Ventures |
| Jan 1, 2012 | Joule Unlimited Technologies | $70.0M Series C | — | ARCH Venture Partners, Borealis Ventures, Catalio Capital, Flagship Ventures, InterWest, NanoDimension, Polaris Partners, Vivo Capital, Wildcat Ventures |
| Apr 1, 2010 | Joule Unlimited Technologies | $30.0M Series B | — | ARCH Venture Partners, Borealis Ventures, Catalio Capital, Flagship Ventures, InterWest, NanoDimension, Polaris Partners, Vivo Capital, Wildcat Ventures |
